Autopsy report · NCT03755518

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Slow accrual.”

The sponsor’s own words in the registry.

Life of this trial

Registered 5 months before it started.
Ran for about 4 years 7 months before it stopped.
38 participants enrolled.
Results were posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 3
Sponsor: Celgene
Sponsor type: Industry
Conditions: Primary Myelofibrosis; Post-Polycythemia Vera Myelofibrosis; Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Interventions: FEDRATINIB
Participants: 38
Sites: 35
Countries: Canada, United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.